Intercell Executes Multi-Year Contract for Supply of IXIARO to the United States Military
First sales of IXIARO under this military contract expected soon
Intercell AG announced that the Company has successfully entered into a multi-year contract with the Defense logistics Agency (DLA), Defense Supply Center of the U.S. Department of Defense to supply IXIARO, a vaccine against Japanese encephalitis (JE). The first sales of IXIARO under this contract are expected in the near future.
This supply contract was negotiated in response to a Request for Proposals (RFP) issued by the DLA in August 2008. The parties were able to move forward to finalize the contract after IXIARO was approved by the Food and Drug Administration on March 30. The major terms of this contract are as follows:
- Exclusive contract for Intercell to supply DLA with all their requirements for JE vaccine
- Five-year contract, with annual options for price modifications
IXIARO was developed by Intercell under an agreement with the Walter Reed Army Institute of Research (WRAIR).
Intercell will directly distribute and market IXIARO to the U.S. military. Novartis Vaccines USA will market and distribute the vaccine to the private market in the U.S.
Other news from the department research and development
